Osteoporosis News

Women with osteoporosis are not being identified and treated at sufficient rates, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

Osteoporosis therapies work equally well for women at high risk for fracture with high or low bone mineral density, according to data from the virtual American Society for Bone and Mineral Research Annual Meeting.

The Endocrine Society updated its osteoporosis clinical practice guideline to include recommendations for romosozumab, noting that the monthly injection therapy is an “effective option” for postmenopausal women at high risk for fracture, according to a society press release.

Postmenopausal women with osteoporosis who received a single infusion of zoledronate after 2 to 5 years of denosumab therapy retained more than half of bone mineral density gained before stopping treatment with no increase in vertebral fractures, according to findings published in the Journal of Bone and Mineral Research.

NEW ORLEANS — A new guideline from the Endocrine Society outlines current evidence for treating osteoporosis in postmenopausal women and provides recommendations on the newest, most effective medication options, monitoring and more.

In an update to its 2011 recommendations, the U.S. Preventive Services Task Force recommends screening with bone measurement testing to prevent osteoporotic fractures in women aged at least 65 years and in postmenopausal, high-risk women younger than 65 years.